Type(s) of chemotherapy-ABVD - Page 2 of 2 Posts on Medivizor
Navigation Menu

Type(s) of chemotherapy-ABVD Posts on Medivizor

Does liposomal doxorubicin improve heart side effects in lymphoma patients compared to conventional doxorubicin?

Does liposomal doxorubicin improve heart side effects in lymphoma patients compared to conventional doxorubicin?

Posted by on Feb 27, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the impact of liposomal doxorubicin (Adriamycin) on cardiac side effects in lymphoma patients compared to conventional doxorubicin. The study suggested that liposomal doxorubicin can reduce cardiac effects and still be an effective therapy, particularly for patients at high risk for anthracycline-induced...

Read More

What are the long-term outcomes for early-stage HL patients who received radiotherapy alone or combined with chemotherapy?

What are the long-term outcomes for early-stage HL patients who received radiotherapy alone or combined with chemotherapy?

Posted by on Feb 15, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined long-term risk of death from all causes using data from 1,541 early-stage (stage 1-2) Hodgkin’s lymphoma (HL) patients who received radiotherapy (RT) alone or RT with chemotherapy. This study concluded that this risk was significantly lower for patients treated in the most recent era of radiation therapy thanks...

Read More

What are the outcomes for advanced HL patients receiving intensified BEACOPP chemotherapy after ABVD chemotherapy?

What are the outcomes for advanced HL patients receiving intensified BEACOPP chemotherapy after ABVD chemotherapy?

Posted by on Feb 9, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the outcomes of advanced-stage classical Hodgkin’s lymphoma (HL) patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by escalated (higher dose) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) chemotherapy...

Read More

What are the outcomes for early-stage HL patients treated with ABVD and radiotherapy alone?

What are the outcomes for early-stage HL patients treated with ABVD and radiotherapy alone?

Posted by on Jan 16, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined the outcomes of early-stage classical Hodgkin’s lymphoma (HL) patients who received ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy and radiotherapy (RT) only. The study concluded that patients who showed a good partial response (tumor shrinkage) to ABVD chemotherapy were successfully...

Read More

Risk of heart failure in survivors of Hodgkin lymphoma treated with anthracyclines and/or chest radiation

Risk of heart failure in survivors of Hodgkin lymphoma treated with anthracyclines and/or chest radiation

Posted by on Feb 23, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors looked at the relationship between heart failure and different treatments for Hodgkin Lymphoma. This study concluded that the risk of heart failure increased with increasing radiation doses and the use of chemotherapy containing anthracyclines (such as doxorubicin). Some background Hodgkin lymphoma (HL) has high 10-year...

Read More

Reducing time between salvage chemotherapy cycles in relapsed or refractory Hodgkin lymphoma

Posted by on Jan 20, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined whether a faster course of salvage chemotherapy reduced tumor volume in patients with relapsed or refractory Hodgkin lymphoma. The authors concluded that shorter intervals between SC cycles was safe and effective. Some background Hodgkin lymphoma is considered to be a highly curable form of...

Read More